Majewska‐Pulsakowska 2016.

Study characteristics
Methods	Study design: RCT Study grouping: parallel‐group
Participants	Baseline characteristics PR+IMT N (randomized/analyzed): 13/13 Loss to follow‐up or excluded: 0 Age, mean (SD) in years: 61.5 (6.1) Gender (M/F): 10/3 BMI, mean (SD), kg/m²: 28.8 (6.2) PR N (randomized/analyzed): 9/9 Loss to follow‐up or excluded: 0 Age, mean (SD) in years: 62.3 (5.2) Gender (M/F): 6/3 BMI, mean (SD), kg/m²: 28.2 (6.2) IMT N (randomized/analyzed): 8/8 Loss to follow‐up or excluded: 0 Age, mean (SD) in years: 63.4 (9.8) Gender (M/F): 2/6 BMI, mean (SD), kg/m²: 26.1 (5.9) Control/sham N (randomized/analyzed): 13/13 Loss to follow‐up or excluded: 0 Age, mean (SD) in years: 65.5 (7.0) Gender (M/F): 7/6 BMI, mean (SD), kg/m²: 27.8 (4.9) Overall N (randomized/analyzed): 43/43 Loss to follow‐up or excluded: 0 Gender (M/F): 25/18 COPD stage (GOLD): moderate to severe Included criteria COPD treated for at least 1 year, stage 2 and 3 according to GOLD (2014) 50–70 years old A stable clinical condition with no exacerbations over the period of 4 weeks before the study Excluded criteria Participation in PR in the year preceding the study Diagnosed bronchial asthma Long‐term home oxygen therapy Clinically significant diseases of the cardiovascular system Any uncontrolled chronic disease; muscle and nervous disorders reducing the patient's mobility Mental disorders preventing contact and co‐operation with the patient
Interventions	Intervention characteristics PR: consisted of training on a cycle ergometer, 3 times/week for 8 weeks in an ambulatory setting under the supervision of a cardiologist. Each training session began (warm‐up) and finished (relaxation) with a pedalling load of 10 W for 3 min. The duration of a training session was initially 23 min, and then it was gradually increased up to 45 min. IMT: consisted of home‐based training using Threshold IMT device (Respironics; Philips Healthcare, DA Best, The Netherlands), twice a day (5‐15 min), 5 d/week for 8 weeks. The training load ranged from 30%‐60% of PImax PR+IMT: this group received both interventions described above. Control/sham: this group did not receive any intervention.
Outcomes	HRQoL: SGRQ Respiratory function: FEV1  L %pred
Identification	Country: Poland Author's name: K. Wytrychowski Institution: Department of Internal Diseases, Geriatry andAllergology, Wroclaw Medical University Email: Polande‐mail:anhw@op.plK Address: 66 Sklodowskiej‐Curie St., 50‐369 Wroclaw, Poland
Notes